Adult ID

Pediatric ID

Epi/Infection Control

Investigative ID

Symposium

21 - We're Part of the Problem: How ID Killed Antibiotic Development

Presentations:

• 10:30 AM - 10:40 AM

  47 - Introduction
  Helen Boucher, MD – Tufts Medical Center
• 10:40 AM - 11:00 AM

  48 - Industry Perspective
  Chen Yu, Dr. – Vivo Capital
• 11:00 AM - 11:45 AM

  49 - Moderated Panel Discussion
  Alan Carr, PhD – Needham & Co.; Kevin Outterson, JD, LLM – Boston University & CARB-X; Manos Perros; Chau Khuong

Moderator(s)

• 

  Helen Boucher, MD

  Director, Tufts Center for Integrated Management of Antimicrobial Resistance
  Tufts Medical Center
  Boston, MA

  Disclosure: Nothing to disclose
• VF

  Vance Fowler, Jr., MD, MHS

  Professor of Medicine
  Duke University
  Durham, North Carolina

  Disclosure: Green Cross, Cubist, Cerexa, Durata, Theravance
  Debiopharm: Educational fees, Other Financial or Material Support
  MedImmune, Cerexa/Forest/Actavis/Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Cubist/Merck
  Medical Biosurfaces
  Locus
  Affinergy
  Contrafect
  Karius
  Genentech, Regeneron, Basilea: Research Grant
  Pfizer, Novartis, Galderma, Novadigm, Durata, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetraphase, Trius, MedImmune, Bayer, Theravance, Cubist, Basilea, Affinergy, Janssen, xBiotech, Contrafect, Regeneron, Basilea, Destiny.: Consultant
  UpToDate: Other Financial or Material Support, Royalties

Panelist(s)

• AC

  Alan Carr, PhD

  Managing Director
  Needham & Co.
  New York, NY

  Disclosure: Nothing to disclose
• 

  Kevin Outterson, JD, LLM

  Professor & Executive Director
  Boston University & CARB-X
  Boston, MA

  Disclosure: Nothing to disclose
• MP

  Manos Perros
• CK

  Chau Khuong

Speaker(s)

• 

  Helen Boucher, MD

  Director, Tufts Center for Integrated Management of Antimicrobial Resistance
  Tufts Medical Center
  Boston, MA

  Disclosure: Nothing to disclose
• CY

  Chen Yu, Dr.

  Managing Partner
  Vivo Capital